$DOX

Amdocs (NASDAQ:DOX) posts Q3 CY2026 sales in line with estimates but stock drops 40.3%

Amdocs (DOX) reported Q3 CY2026 revenue of $1.19B, meeting estimates, with a 3.8% YoY increase. However, Q4 guidance of $975M missed expectations by 18.7%. Adjusted EPS was $1.98, in line with estimates. The stock dropped 40.3% post-earnings. CEO highlighted new strategic deals, including an 8-year agreement with AT&T.

Original reporting
Published Nov 3, 2026, 10:23 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 10:40 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Amdocs (NASDAQ:DOX) posts Q3 CY2026 sales in line with estimates but stock drops 40.3% — source image
Decision brief

The 30-second read

$DOXBearishHigh
01

Why it matters

The earnings miss and weak guidance triggered a 40% price decline, indicating immediate market reaction.

02

Market read

Amdocs' earnings and guidance miss are the primary drivers of the stock's sharp move, with potential ripple effects in the telecom software sector.

03

What to watch

Amdocs' new aOS deals with AT&T, Vodafone, VEON, and Globe could drive mid‑term growth despite short‑term guidance miss.

Relevance 9/10Novelty 9/10Timing: after-hours reaction

Background

Amdocs is a leading provider of telecom software solutions, recently announcing strategic agreements with major carriers.

Company-level read

Ticker impact

$DOXBearishHigh confidence
Context

Amdocs reported Q3 CY2026 results in line with estimates but issued Q4 guidance 18.7% below consensus, causing a 40.3% share drop.

Expected impact

likely further downside as investors price in weak Q4 outlook

Evidence & confidence

Guidance shortfall is material and the stock already fell 40% on the news; market reaction is expected to continue.

Market effects

Telecom software sector may see broader scrutiny of guidance expectations.

North American tech indices could face short-term pressure.

Limited to investors tracking telecom software and enterprise software stocks.

Counterpoint

The stock may be oversold; a deeper pullback could set up a buying opportunity if guidance improves.

Key entities

  • Amdocs

    Telecom software provider reporting Q3 CY2026 results.

  • AT&T

    Largest customer in a new eight‑year strategic agreement.

Related articles

$DOXHighAI 9/10

Amdocs (DOX) Q4 2026 Earnings Call Transcript

Amdocs (DOX) announced an 8-year deal with AT&T and other strategic agreements with VEON, Globe, and VodafoneThree to adopt its AOS technology. The company also acquired EIS, an insurance software provider, for $340M. Amdocs plans to expand into the insurance market and has optimized its portfolio to focus on its agentic strategy. The company reported progress in internal transformation and provided FY2027 revenue growth guidance.

$DOXMedAI 8/10

Amdocs share price tanks as T-Mobile US dispute weighs heavily

Amdocs' share price dropped 42% after reporting a 3.6% revenue rise to $4.7bn, due to a contract dispute with T-Mobile US. The dispute may lead to arbitration or legal action, and Amdocs expects a 7-11% revenue decline in the coming year. Despite this, Amdocs secured new contracts with Vodafone, AT&T, and others, and acquired EIS for $340m to expand into insurance technology.

$DOXHighAI 9/10

Amdocs drama: Stock crashes 45%

Amdocs' stock fell 45% after hours due to a weak 2027 forecast tied to a legal dispute with T-Mobile. The company reported a 9.6% drop in its 12-month order backlog to $3.5B and annual revenue of $4.7B, up 3.5%. Amdocs also announced a new contract with AT&T and acquired EIS for $340M to expand into insurance.

$DOXHighAI 9/10

Why is Amdocs stock cratering 40% today?

Amdocs stock fell 39.4% to $37.83 after issuing a weak fiscal 2027 outlook due to a legal dispute with T-Mobile, its largest customer. Q4 2026 results met expectations, but FY2027 revenue is projected to decline 14.3%-17.9% and adjusted EPS to fall 26%-30%. Oppenheimer downgraded the stock, and analysts revised earnings forecasts downward. The company also announced a $340M acquisition, adding to financial pressures.